Respiratory Adverse Events of Weight-Loss Drugs: A Systematic Review and Meta-Analysis
This systematic review and meta-analysis pooled 123 studies evaluating respiratory adverse events of weight-loss drugs largely in general populations, with only one study specific to asthma patients. Liraglutide, semaglutide, tirzepatide, and naltrexone-bupropion showed no increased respiratory adverse events versus placebo, though nasopharyngitis and upper respiratory infections were common across drugs regardless of dose. Overall trial quality was rated low risk of bias, but evidence specific to asthmatic patients remains sparse, limiting firm conclusions for that subgroup. Urgent Care clinical implications: There was no evidence of increased respiratory harm associated with weight-loss drugs compared with placebo, suggesting a reassuring respiratory safety profile in the general population. However, evidence specifically focused on individuals with asthma remains limited. Full Access: Annals of the American Thoracic Society
Reliability of Physical Examination Findings in Youths Diagnosed With Pneumonia
A national PECARN-affiliated study led by Lurie Children’s Hospital of Chicago examined 252 children diagnosed with community-acquired pneumonia in emergency departments and found substantial disagreement between examiners on key auscultatory findings, including crackles, decreased breath sounds, and rhonchi. This mirrors earlier work (Florin et al., 2017) showing only fair-to-moderate interrater reliability for most CAP exam findings, with just wheezing, retractions, and respiratory rate reaching acceptable agreement. The authors conclude that physical exam alone is often insufficient to confidently diagnose pediatric pneumonia, reinforcing the value of adjunctive data. Urgent Care clinical implications: Current guidelines, including those from the Infectious Diseases Society of America, recommend that clinicians rely on physical examination findings to diagnose pediatric CAP in outpatient settings. However, the substantial variability in how these findings are recognized across clinicians suggests that use of auscultatory findings alone is not a reliable method for diagnosing CAP in youths. Full Access: JAMA
Whole-Blood Point-Of-Care Glial Fibrillary Acidic Protein and Ubiquitin C-Terminal Hydrolase L1 Biomarkers After Traumatic Brain Injury in the US: A Prospective Diagnostic Prediction of Intracranial Injury on Head CT
This prospective, multicenter regulatory trial showed biomarkers have a 96.5% sensitivity and 96.5% negative predictive value for detecting traumatic intracranial CT abnormalities, with a 3.5% false negative rate, and none of the false negatives required neurosurgical intervention. Specificity was lower at 40.3%, and all 14 lesions requiring potential neurosurgical intervention were correctly flagged as “elevated” by the test. The biomarkers are FDA-approved and now included in the ACS Trauma Quality Program 2024 Best Practices Guidelines for reducing unnecessary CT imaging. Urgent Care clinical implications: A negative point-of-care GFAP/UCH-L1 result (within 12–24h of injury) can support safely deferring head CT and considering outpatient management/referral for a stable mild-TBI patient (GCS 15), while an elevated result still warrants ED referral for imaging given the test’s low specificity (high false-positive rate). Full Access: The Lancet
FDA Authorizes Avulux Lens for Migraine-Related Light Sensitivity
The FDA granted De Novo marketing authorization to Avulux, an optical filtering lens for patients 12 and older with episodic migraine-associated light sensitivity — the first FDA-recognized device class in this category. Unlike traditional sunglasses, the lenses selectively filter light at 480nm (high blue) and 590nm (red/amber) wavelengths linked to triggering or worsening migraine attacks, while letting the rest of the visible spectrum through. It’s intended as a nonpharmacologic adjunct to standard migraine care, not a replacement, and is available over the counter. Urgent Care clinical implications: For patients presenting with acute migraine and prominent photophobia, this offers a low-risk, non-drug adjunct clinicians can mention alongside standard abortive therapy — but evidence for direct pain relief is modest and it shouldn’t delay or substitute for appropriate pharmacologic treatment, especially in moderate-to-severe attacks. Full Access: MRP